Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 8, 2009, Pages 913-923

  Falagas, Matthew E ^a,b   Metaxas, Eugenios I ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; Community acquired pneumonia; Glycylcyclines; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DIGOXIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; PLACEBO; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ACUTE PANCREATITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHLEBITIS; POSTMARKETING SURVEILLANCE; PREGNANCY; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; GUINEA PIGS; HOSPITALIZATION; HUMANS; LUNG; MINOCYCLINE; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 70350605550     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.73     Document Type: Review

References (73)

1. Kung H-C, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat. Rep. 56(10), 1-121 (2008).
2. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat. Rep. 57(14), 1-80 (2009).
3. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 125(6), 2140-2145 (2004). (Pubitemid 38788182)
4. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob. Agents Chemother. 51(12), 4382-4389 (2007).
5. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A metaanalysis. JAMA 275(2), 134-141 (1996).
6. File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect. Dis. Clin. North Am. 18(4), 993-1016 (2004).
7. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit. Care 10(Suppl. 2), S1 (2006).
8. Niederman MS. Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Med. Clin. North Am. 85(6), 1493-1509 (2001).
9. Lim WS, Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58(5), 377-382 (2003). (Pubitemid 36560938)
10. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336(4), 243-245 (1997).
11. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007). • Latest guidelines for community-acquired pneumonia (CAP) management in the USA.
12. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26(6), 1138-1180 (2005). (Pubitemid 41829947)
13. Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 179(12), 1269-1277 (2008).
14. Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 68(17), 2469-2481 (2008).
15. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short-versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 68(13), 1841-1854 (2008).
16. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J. Antimicrob. Chemother. 62(4), 661-668 (2008).
17. Peterson LR. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline. Diagn. Microbiol. Infect. Dis. 52(3), 163-164 (2005).
18. Pankey GA. Tigecycline. J. Antimicrob. Chemother. 56, 470-480 (2005). • Well-written review about tigecycline.
19. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41(Suppl. 5), S303-S314 (2005).
20. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis. 52(3), 173-179 (2005). (Pubitemid 41133542)
21. Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44(4), 1085-1088 (2000).
22. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 47(2), 533-540 (2003).
23. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother. 62(1), 45-55 (2008). (Pubitemid 351865873)
24. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin. Ther. 28(8), 1079-1106 (2006).
25. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20(9 Pt 2), 219S-223S (2000).
26. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin Ther. 27, 12-22 (2005).
27. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43(4), 738-744 (1999).
28. Bergeron J, Ammirati M, Danley D et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. 40(9), 2226-2228 (1996). (Pubitemid 26296281)
29. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int. J. Antimicrob. Agents 25(3), 185-192 (2005).
30. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin. Infect. Dis. 43(4), 518-524 (2006).
31. Livermore DM. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56(4), 611-614 (2005).
32. Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. 6(4), 277-282 (2000).
33. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49(1), 220-229 (2005).
34. Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 44(4), 943-949 (2000). (Pubitemid 30165274)
35. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41(Suppl. 5), S333-S340 (2005).
36. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr. Drug Metab. 10(1), 13-21 (2009).
37. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5), S315-S332 (2005).
38. Bradford PA. Tigecycline: a first in class glycylcycline. Clin. Microbiol. Newslett. 26(21), 163-168 (2004).
39. Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir. Med. 99(60), 60-65 (2005). (Pubitemid 40017385)
40. Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin. Chest Med. 26(1), 47-55 (2005).
41. Gillet Y, Vanhems P, Lina G et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton- Valentine leukocidin. Clin. Infect. Dis. 45(3), 315-321 (2007). (Pubitemid 47101027)
42. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton - Valentine leukocidin genes. Clin. Infect. Dis. 40(1), 100-107 (2005). (Pubitemid 40053465)
43. Fritschea TR, Sadera HS, Stilwella MG, Dowzickyb MJ, Jonesa RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 52(3), 187-193 (2005).
44. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45(9), 2604-2608 (2001).
45. Salvatore CM, Techasaensiri C, Tagliabue C et al. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother. 53(4), 1546-1551 (2009).
46. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int. J. Antimicrob. Agents 16(1), 61-63 (2000).
47. Muralidharan G, Mojaverian P, Micalizzi M et al. The effects of age and gender on the pharmacokinetics, safety, and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. Presented at: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC, USA, 17-20 September 2000 (Abstract A-502).
48. Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25(6), 523-529 (2005). (Pubitemid 40732607)
49. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62(5), 895-904 (2008).
50. Paterson DL. Clinical experience with recently approved antibiotics. Curr. Opin. Pharmacol. 6(5), 486-490 (2006).
51. Poulakou G, Kontopidou FV, Paramythiotou E et al. Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J. Infect. 58(4), 273-284 (2009).
52. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52(3), 181-186 (2005).
53. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58(6), 1221-1229 (2006). (Pubitemid 44884142)
54. Hoffman H, DeMaio W, Jordan RA et al. Metabolic disposition of [14C] tigecycline in human volunteers following intravenous infusion. AAPS PharmSci. 6(Suppl. 1), (2004) (Abstract 2540).
55. Troy SM, Muralidharan G, Micalizzi M, Mojovarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) . Presented at: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC, USA (2003) (Abstract A-43).
56. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am. J. Health-Syst. Pharm. 63(13), 1235-1243 (2006). (Pubitemid 44025089)
57. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int. J. Antimicrob. Agents 34(1), 101-102 (2009).
58. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 Phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 61(3), 329-338 (2008). (Pubitemid 351858575)
59. Bergallo C, Jasovich A, Teglia O et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized Phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 63(1), 52-61 (2009). •• This Phase III clinical trial was conducted in north, south and central America (Study 308).
60. Dartois N, Castaing N, Gandjini H, Cooper A; Tigecycline 313 Study Group. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J. Chemother. 20(Suppl. 1), 28-35 (2008). •• This Phase III clinical trial was conducted in Europe, Africa and the Asia-Pacific Region (study 313).
61. Stein GE. Safety of newer parenteral antibiotics. Clin. Infect. Dis. 41(Suppl. 5), 293-302 (2005).
62. Zimmerman JJ, Harper D, Matschek K. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October-2 November 2004.
63. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation, Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52(3), 215-227 (2005).
64. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob. Agents Chemother. 50(10), 3479-3484 (2006).
65. File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J. Manag. Care Pharm. 15(2 Suppl.), S5-S11 (2009). • Recent review about CAP management.
66. Websites 101 BTS Pneumonia Guidelines Committee. British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Adults - 2004 Update www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Pneumonia/ Guidelines/MACAPrevisedApr04.pdf (Accessed 27 July 2009) • Latest guidelines for CAP management by the British Thoracic Society.
67. Wyeth Pharmaceuticals Inc. United States Package Insert www.wyeth.com/content/showlabeling.asp?id=491 (Accessed 27 July 2009)
68. European Medicines Agency. Withdrawal Assessment Report www.emea.europa.eu/humandocs/PDFs/EPAR/tygacil/Tygacil%20II-13-AR.pdf (Accessed 27 July 2009) • Detailed report of the European Medicines Agency regarding the use of tigecycline in CAP.
69. EMEA. Summary of product Characteristics www.emea.europa.eu/humandocs/ PDFs/EPAR/tygacil/H-644-PIen.pdf (Accessed 27 July 2009)
70. Tigecycline Evaluation Surveillance Trial (TEST) www.testsurveillance.com (Accessed 27 July 2009)
71. European Medicines Agency. Questions and Answers on the withdrawal of the application for a change to the marketing authorization for Tygacil www.emea.europa.eu/humandocs/PDFs/EPAR/tygacil/24577108en.pdf (Accessed 27 July 2009)
72. Wyeth Europa Limited. Withdrawal of Application www.emea.europa.eu/ humandocs/PDFs/EPAR/tygacil/withdrawalletter.pdf (Accessed 27 July 2009)
73. Tigecycline Clinical Trials http://clinicaltrials.gov/ct2/results?term= tigecycline (Accessed 27 July 2009)